Compugen Ltd. (CGEN)
NASDAQ (CM) NASDAQ (CM) Primary 
TASE 
Compugen Ltd. (CGEN) Q3 2025 Earnings Call Transcript
Compugen Ltd. ( CGEN ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Yvonne Naughton - Head of Investor Relations & Corporate Communications Eran Ophir - CEO & Director David Silberman - Chief Financial Officer Michelle Mahler - Chief Medical Officer Conference Call Participants Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Daina Graybosch - Leerink Partners LLC, Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Asthika Goonewardene - Truist Securities, Inc., Research Division Swayampakula Ramakanth - H.C.
Compugen (CGEN) Reports Q3 Loss, Lags Revenue Estimates
Compugen (CGEN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to earnings of $0.01 per share a year ago.
Compugen: Potential Best-In-Class Anti-PVRIG COM701 Shifts To Targeting PSOC Patients
Compugen is advancing its anti-PVRIG antibody COM701 in phase 1/2 as a maintenance therapy for relapsed platinum-sensitive ovarian cancer patients, with interim data expected in 2H 2026. Positive proof-of-concept in platinum-resistant ovarian cancer and strong partnerships with AstraZeneca and Gilead provide multiple value-creation opportunities and financial stability. Upcoming catalysts include ESMO 2025 data releases for COM701 and AstraZeneca-partnered rilvegostomig in solid tumors, offering potential stock-moving events.
Compugen Ltd. (CGEN) Q2 2025 Earnings Call Transcript
Compugen Ltd. (NASDAQ:CGEN ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants Anat Cohen-Dayag - CEO, President & Director David Silberman - Chief Financial Officer Eran Ophir - Chief Scientific Officer Michelle Mahler - Chief Medical Officer Yvonne Naughton - Head of Investor Relations & Corporate Communications Conference Call Participants Leland James Gershell - Oppenheimer & Co. Inc., Research Division Operator Ladies and gentlemen, thank you for joining us today.
Compugen (CGEN) Reports Q2 Loss, Lags Revenue Estimates
Compugen (CGEN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.02 per share a year ago.
Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates
Compugen (CGEN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.08 per share a year ago.
Compugen Ltd. (CGEN) Q1 2025 Earnings Call Transcript
Compugen Ltd. (NASDAQ:CGEN ) Q1 2025 Earnings Conference Call May 19, 2025 8:30 AM ET Company Participants Yvonne Naughton - VP, Head of IR & Corporate Communications Anat Cohen-Dayag - President & CEO David Silberman - CFO Michelle Mahler - Chief Medical Officer Eran Ophir - Chief Scientific Officer Conference Call Participants Daina Graybosch - Leerink Partners Rohan Mathur - Oppenheimer Asthika Goonewardene - Truist Operator Ladies and gentlemen, thank you for joining us today.
Compugen Ltd. (CGEN) Q4 2024 Earnings Call Transcript
Compugen Ltd. (NASDAQ:CGEN ) Q4 2024 - Earnings Conference Call March 4, 2025 8:30 AM ET Company Participants Yvonne Naughton - VP, Head of IR and Corporate Communications Anat Cohen-Dayag - President and CEO David Silberman - CFO Michelle Mahler - Chief Medical Officer Eran Ophir - Chief Scientific Officer Conference Call Participants Karina Rabayeva – Truist Securities Daina Graybosch - Leerink Partners Leland Gershell - Oppenheimer Tony Butler - Rodman and Renshaw Stephen Willey - Stifel Operator Ladies and gentlemen, thank you for joining us today.
Compugen (CGEN) Reports Q4 Loss, Misses Revenue Estimates
Compugen (CGEN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.07. This compares to earnings of $0.11 per share a year ago.
Compugen: Immuno-Oncology Innovator Poised For A Comeback
Compugen's innovative approach targets under-explored immune pathways like PVRIG and IL-18 binding protein, offering potential upside, despite current market skepticism. With $113.2 million in cash and milestone payments from Gilead and AstraZeneca, Compugen has a solid financial runway extending into 2027. Compugen's pipeline, including COM701 and COM503, aims to transform tumor responsiveness through unique immunotherapy strategies, potentially reshaping the immuno-oncology landscape.
Compugen initiated with bullish view at Oppenheimer, here's why
Compugen +0.05 (+3.14%) AstraZeneca +0.44 (+0.66%) Gilead +0.7 (+0.79%)
Compugen Ltd. (CGEN) Q3 2024 Earnings Call Transcript
Start Time: 08:30 January 1, 0000 9:30 AM ET Compugen Ltd. (NASDAQ:CGEN ) Q3 2024 Earnings Call November 12, 2024, 08:30 AM ET Company Participants Anat Cohen-Dayag - President and CEO David Silberman - CFO Michelle Mahler - Chief Medical Officer Eran Ophir - Chief Scientific Officer Oladapo Yeku - Assistant Professor of Medicine, Harvard Medical School, and Director of Translational Research, Gynecologic Oncology Program Yvonne Naughton - Head of IR and Corporate Communications Conference Call Participants Stephen Willey - Stifel Daina Graybosch - Leerink Partners Tony Butler - Rodman and Renshaw Asthika Goonewardene - Truist Securities Operator Ladies and gentlemen, thank you for joining us today.
